Establishment and characterization of therapy-resistant mantle cell lymphoma cell lines derived from diff erent tissue sites

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2269-2278

  Ahrens, Adam K ^a   Chaturvedi, Nagendra K ^a   Nordgren, Tara M ^a   Dave, Bhavana J ^b   Joshi, Shantaram S ^a  

^a NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

gene expression analyses; Mantle cell lymphoma; therapy resistant cell lines

Indexed keywords

AGAR; BORTEZOMIB; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; VINCRISTINE;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CELL GROWTH; CELL STRUCTURE; CONTROLLED STUDY; CYTOGENETICS; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOPHENOTYPING; KIDNEY; LIVER; LUNG; LYMPHOMA CELL; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; CELL LINE, TUMOR; CHROMOSOME ABERRATIONS; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMANS; IMMUNOPHENOTYPING; LYMPHOMA, MANTLE-CELL; MICE; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR MICROENVIRONMENT;

EID: 84867164906     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.691481     Document Type: Article

References (37)

1. Bertoni F, Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007;39:1747-1753. (Pubitemid 47321342)
2. Gao J, Peterson L, Nelson B, et al. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009;132:699-706.
3. Zucca E, Stein H, Coifier B. European Lymphoma Task Force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994;5:507-511. (Pubitemid 24223502)
4. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007;7:750-762. (Pubitemid 47463673)
5. Dreyling M, Hiddemann W. Current treatment standards and emerging strategies in mantle cell lymphoma. Hematology 2009:1; 542-551.
6. Ghielmini M, Zucca E. How I treat mantle cell lymphoma. Blood 2009;114:1469-1476.
7. Foran JM, Cunningham D, Coifier B, et al. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response. Ann Oncol 2000;11:117-121.
8. Fisher RI, Bernstein SH, Kahl BS, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006;24:4867-4874. (Pubitemid 46655613)
9. Habermann TM, Lossos IS, Justice G, et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344-349.
10. Dreyling M, Lenz G, Hoster E, et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission signif cantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005;105:2677-2684. (Pubitemid 40450320)
11. Jares P, Campo E. Advances in the understanding of mantle cell lymphoma. Br J Heamatol 2008;142:149-165. (Pubitemid 351994053)
12. Kurtova AV, Tamayo AT, Ford RJ, et al. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specif c targeting. Blood 2009;113:4604-4613.
13. Coupland SE. The challenge of the microenvironment in B-cell lymphomas. Histopathology 2011;58:69-80.
14. Lai R, McDonnell TJ, O'Connor SL, et al. Establishment and characterization of a new mantle cell lymphoma cell line, Mino. Leuk Res 2002;26:849-855. (Pubitemid 34778500)
15. Rudolpha C, Steinemanna D, von Neuhof a N, et al. Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519. Cancer Genet Cytogenet 2004;153:144-150.
16. Jeon HJ, Kim CW, Yoshino T, et al. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998;102:1323-1326. (Pubitemid 28435219)
17. Amin HM, McDonnell TJ, Medeiros LJ, et al Characterization of 4 mantle cell lymphoma cell lines. Arch Pathol Lab Med 2003;127:424-431.
18. Joshi SS, Sharp JG, Brunson KW. Dif erential growth characteristics of low and high metastatic variant RAW117 murine lymphosarcoma cells. Oncology 1987;44:180-185. (Pubitemid 17103284)
19. Dave BJ, Nelson M, Sanger WG. Lymphoma cytogenetics. Clin Lab Med 2011;31:725-761.
20. Joshi AD, Hegde GV, Dickinson JD, et al. ATM, CTLA4, MNDA, and HEM1 in high versus low CD38 expressing B-cell chronic lymphocytic leukemia. Clin Cancer Res 2007;13:5295-5304. (Pubitemid 47510353)
21. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2004;98:5116-5121.
22. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression prof les. Proc Natl Acad Sci USA 2005;102:15545-15550. (Pubitemid 41528093)
23. Hegde GV, Nordgren TM, Munger CM, et al. Novel therapy for therapy-resistant mantle cell lymphoma: multipronged approach with targeting hedgehog signalling. Int J Cancer 2012 Apr 17. [Epub ahead of print]
24. Golardi N, Velasco MR, Elghetany MT. Marginal zone variant of mantle cell lymphoma: CD5-negative cyclin D1-positive variant posing a diagnostic dilemma. Pathol Int 2009;59:317-321.
25. Zapata M, Budnick SD, Bordoni R, et al. An uncommon case of de novo CD10 + CD5-mantle cell lymphoma mimics follicle center B cell lymphoma. Int J Clin Exp Pathol 2010;3:430-436.
26. Lai R, Weiss LM, Chang KL, et al. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43 + follicular lymphomas. Am J Clin Pathol 1999;111:488-494. (Pubitemid 29153144)
27. Schlette E, Fu K, Medeiros LJ. CD23 expression in mantle cell lymphoma: clinicopathologic features of 18 cases. Am J Clin Pathol 2003;120:760-766. (Pubitemid 37339685)
28. Yasuhara T, Okamoto A, Kitagawa T, et al. FGF7-like gene is associated with pericentric inversion of chromosome 9, and FGF7 is involved in the development of ovarian cancer. Int J Oncol 2005;26:1209-1216.
29. Haddadin MH, Hawkins AL, Long P, et al. Cytogenetic study of malignant triton tumor: a case report. Cancer Genet Cytogenet 2003;144:100-105. (Pubitemid 36808955)
30. Rao PH, Houldsworth J, Dyomina K, et al. Chromosomal and gene amplif cation in diffuse large B-cell lymphoma. Blood 1998;92:234-240. (Pubitemid 28303198)
31. Camps J, Salaverria I, Garcia MJ, et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 2006;30:923-934. (Pubitemid 43831180)
32. Hao S, Sanger W, Onciu M, et al. Mantle cell lymphoma with 8q24 chromosomal abnormalities : a report of 5 cases with blastoid features. Mod Pathol 2002;15:1266-1272. (Pubitemid 35462993)
33. Zhao JJ, Lin J, Lwin T, et al. MicroRNA expression prof le and identif cation of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma. Blood 2010;115:2630-2639.
34. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:5683-5690.
35. Enjuanes A, Fernandez V, Hernandez L, et al. Identification of methylated genes associated with aggressive clinicopathological features in mantle cell lymphoma. PLoS One 2011;6:e19736.
36. Ripperger T, von Neuhof N, Kamphues K, et al. Promoter methylation of PARG1, a novel candidate tumor suppressor gene in mantle cell lymphomas. Haematologica 2007;92:460-468. (Pubitemid 350144291)
37. Leshchenko V, Kuo P, Shaknovich R, et al. Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood 2010;116:1025-1034.